ATE208421T1 - Stimulierung der immunantwort durch virales protein - Google Patents

Stimulierung der immunantwort durch virales protein

Info

Publication number
ATE208421T1
ATE208421T1 AT94909182T AT94909182T ATE208421T1 AT E208421 T1 ATE208421 T1 AT E208421T1 AT 94909182 T AT94909182 T AT 94909182T AT 94909182 T AT94909182 T AT 94909182T AT E208421 T1 ATE208421 T1 AT E208421T1
Authority
AT
Austria
Prior art keywords
stimulation
protein
peptide
immune response
viral protein
Prior art date
Application number
AT94909182T
Other languages
English (en)
Inventor
Christian Ertel
Hoegen Paul Von
Volker Schirrmacher
Original Assignee
Hoegen Paul Von
Schirrmacher Volker Prof Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoegen Paul Von, Schirrmacher Volker Prof Dr filed Critical Hoegen Paul Von
Application granted granted Critical
Publication of ATE208421T1 publication Critical patent/ATE208421T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94909182T 1993-03-16 1994-03-11 Stimulierung der immunantwort durch virales protein ATE208421T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93301962 1993-03-16
PCT/GB1994/000476 WO1994021798A1 (en) 1993-03-16 1994-03-11 Stimulation of immune response by viral protein

Publications (1)

Publication Number Publication Date
ATE208421T1 true ATE208421T1 (de) 2001-11-15

Family

ID=8214340

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94909182T ATE208421T1 (de) 1993-03-16 1994-03-11 Stimulierung der immunantwort durch virales protein

Country Status (9)

Country Link
EP (1) EP0689596B1 (de)
JP (1) JPH08508641A (de)
KR (1) KR960701208A (de)
AT (1) ATE208421T1 (de)
AU (1) AU675703B2 (de)
CA (1) CA2158461A1 (de)
DE (1) DE69428984T2 (de)
WO (1) WO1994021798A1 (de)
ZA (1) ZA941853B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2310580T3 (es) 1993-04-30 2009-01-16 Wellstat Biologics Corporation Composiciones purificadas del virus de la enfermedad de newcastle.
DE4407538C1 (de) * 1994-03-07 1995-02-23 Deutsches Krebsforsch Bindungsreagens für Zell-Oberflächenprotein und Effektorzelle
WO1995031105A1 (en) * 1994-05-13 1995-11-23 Thomas Jefferson University A method of inducing an immune response using vaccinia virus recombinants
US6093700A (en) 1995-05-11 2000-07-25 Thomas Jefferson University Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
EP1092439A1 (de) 1999-10-13 2001-04-18 Thorsten Dr. Ahlert Aktivierung antigen-spezifischer T-Zellen mit Virus/Antigen-behandelten dendritischen Zellen
AU2003241252A1 (en) 2002-06-06 2003-12-22 Immunicum Ab New method and composition for producing a cellular allogeneic vaccine
WO2005094878A1 (ja) * 2004-03-31 2005-10-13 Genomidea Inc. 抗腫瘍作用を有する組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU602875B2 (en) * 1985-12-18 1990-11-01 British Technology Group Limited Newcastle disease virus gene clones
US5124148A (en) * 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
FR2663228A2 (fr) * 1989-09-29 1991-12-20 Agronomique Inst Nat Rech Composition immunisante contre la maladie de newcastle et procede de preparation.

Also Published As

Publication number Publication date
AU675703B2 (en) 1997-02-13
EP0689596A1 (de) 1996-01-03
AU6247794A (en) 1994-10-11
DE69428984D1 (de) 2001-12-13
ZA941853B (en) 1995-09-18
DE69428984T2 (de) 2002-08-14
KR960701208A (ko) 1996-02-24
EP0689596B1 (de) 2001-11-07
WO1994021798A1 (en) 1994-09-29
JPH08508641A (ja) 1996-09-17
CA2158461A1 (en) 1994-09-29

Similar Documents

Publication Publication Date Title
ATE144143T1 (de) Künstlicher impfstoff gegen aids-virus
ATE334216T1 (de) Impstoff gegen felines immunodefizienz-virus
DK0538437T3 (da) Immunstimulerende og immunforstærkende, rekonstituerede influenzavirosomer og vacciner indeholdende dem
EP1001032A3 (de) Rekombinante Retroviren um Vektorkonstruktionen an Zielzellen zu liefern
KR900700508A (ko) 인간의 호흡기 합포체성 바이러스에 대한 당단백질 면역 단편을 함유하는 키메라(chimeric) 당단백질
AP2000001841A0 (en) Method for obtaining vaccines for preventing the pathgenic effects related to a retroviral infection.
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
ATE241014T2 (de) Hiv-2 varianten
TW377373B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
BR9202024A (pt) Virus de apivox recombinante,cultura de celulas eucariotica infectadas por um virus de avipox,vacina,sequencia de transferencia e plasmideo
FI963717A7 (fi) Uusia mutatoituja viruksia, viruksenvastaisia yhdisteitä ja uusia menetelmiä rokotteiden valmistamiseksi
ATE175119T1 (de) Vakzine gegen immunodefizienz-virus der katze (kiv)
ATE455124T1 (de) Rekombinante vesicular stomatitis viren als impstoff gegen virale hämorrhagische fieber
DE69428984D1 (de) Stimulierung der immunantwort durch virales protein
DE68925660D1 (de) Peptidfragmente von HIV
AR009365A1 (es) Vacunas del virus de la fiebre aftosa (fmdv), peptidos, secuencias de adn y el uso de los peptidos en sistemas de deteccion y el uso de la vacuna fmdc para la preparacion de una composicion para inmunizar cerdos y ganado vacuno
EP0236977A3 (de) Impfstoffe gegen Rindervirus-Diarrhoe und Schweine-Cholera
DK0491713T3 (da) Rubella El-peptider og C-peptider
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
ATE346087T1 (de) Hepatitis e-virus aus dem schwein und dessen verwendungen
ES2160594T3 (es) Antigenos protectores contra la infeccion por echinococcus granulosus y vacunas que contienen estos antigenos.
AR020852A1 (es) Antigenos de vacuna de leptospira para la prevencion de leptospirosis
SE8700466D0 (sv) Vaccines against melanoma
ATE102252T1 (de) Rekombinantes gefluegelpockenvirus, expressionsvektoren fuer heterologische proteine und davon derivierte gefluegelvakzine.
NL300254I1 (nl) Verzwakte herpesvirussen, herpesvirussen die vreemd DNA omvatten dat codeert voor een aminozuur-sequentie en vaccin dat het bevat.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties